Sleep apnoea therapeutic - Bayer
Alternative Names: TASK channel blocker - BayerLatest Information Update: 28 Aug 2022
Price :
$50 *
At a glance
- Originator Bayer
- Class Sleep disorder therapies
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sleep apnoea syndrome
Most Recent Events
- 28 Aug 2022 Bayer Half-Year Financial Report page no 20- Feedback incorporated
- 01 Apr 2022 Discontinued - Phase-I for Sleep apnoea syndrome in Germany (unspecified route) based on results of the Spray Smart study (Bayer Half-Year Financial Report page no 20)
- 26 Aug 2020 Sleep apnoea therapeutic is still in phase II trials for Sleep apnoea syndrome in Germany